Couzin J: Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science. 2004, 306: 384-385.
Couzin J: Clinical Trials: Nail-biting time for trials of drugs. Science. 2004, 306: 1673-1675.
Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc. 2001, 286 (8): 954-959.
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005, 352 (11): 1092-1102.
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005, 352 (11): 1071-1080.
White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002, 89 (4): 425-430.
White WB, Faich G, Borer JS, Makuch RW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor, celecoxib. Am J Cardiol. 2003, 92 (4): 411-418.
Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q: Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002, 89 (2): 204-209.
Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupaci A: Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003, 163 (4): 481-486.
Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullin CD: Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med. 2005, 165 (2): 181-186.
Cancer Statistics, Incidence and Mortality. American Cancer Society. 2004
Harris RE, Beebe-Donk J, Doss H, Burr-Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (Review). Oncology Reports. 2004, 13: 559-583.
Schlesselman JJ: Case Control Studies. 1982, Oxford University Press, New York
Harrell F: Logistic Regression Procedure. Statistical Analysis System (SAS). 2005
Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971, 231: 323-235.
Herschman HR: Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer and Metas Rev. 1994, 13: 241-256.
Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 1992, 89: 7384-7388.
Harris RE: Epidemiology of breast cancer and nonsteroidal anti-inflammatory drugs. COX-2 Blockade in Cancer Prevention and Therapy. Edited by: Harris RE. 2002, Humana Press, Totowa, NJ, 57-68.
Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM: Cyclooxygenase-2 gene expression in human breast cancer. International Journal of Oncology. 1997, 10: 503-507.
Masferrer JL, Leahy KM, Koki AT, Aweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60 (5): 1306-1311.
Abou-Issa HM, Alshafie GA, Harris RE: Chemoprevention of breast cancer by nonsteroidal anti-inflammatory drugs and selective COX-2 blockade in animals. COX-2 Blockade in Cancer Prevention and Therapy. Edited by: Harris RE. 2002, Humana Press, Totowa, NJ, 85-98.
Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by Celecoxib, a specific cyclooygenase-2 (COX-2) inhibitor. Cancer Res. 2000, 60: 2101-2103.
Harris RE, Robertson FM, Farrar WB, Brueggemeier RW: Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP-19): an extension of the dietary fat hypothesis of breast cancer. Medical Hypotheses. 1999, 52 (4): 292-293.
Zhao Y, Agarwal VR, Mendelson CR, Simpson ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 1996, 137 (12): 5739-5742.
Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Letters. 1999, 140 (1–2): 27-35.
Harris RE: Does the dose make the poison?. Science. 2005, 308: 203-